A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Tasman District Council imposed the classification after receiving a report in August last year that Boy had attacked another ...

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

Discover why private ingrown hairs pose more than cosmetic concerns, including infection risks, and learn 6 effective ...

Eventual Australian Survivor: All Stars winner David Genat didn’t have an easy run to landing the title of Sole Survivor. The ...

In the case described in the Equine Veterinary Education Journal, x-rays and hoof testers were not able to predict the location of a subsolar abscess in this horse's foot ...

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...

Recognize early signs of dental problems like sensitivity, bleeding gums, and jaw pain to prevent serious oral health issues.

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

The cause of most concern are seed oils - a type of vegetable oil derived from plant seeds but the cause of most concern are ...